Clinical trials: Combination Chemotherapy
Rectal Cancer
Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
Colorectal cancer is a common gastrointestinal tumor, with rising incidence in China. Rectal cancer accounts for nearly half of new cases, and many patients are diagnosed at a locally advanced stage.
- Trial name
- PUCRT (NCT06770270)
- Testing
- Pucotenlimab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lymphoma
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00003541
- Testing
- filgrastim, CHOP regimen, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Ovarian Cancer, Fallopian Tube Cancer
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy…
- Trial name
- HIPEC (NCT01659554)
- Testing
- Cisplatin, Doxorubicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Stomach Cancer, Gall Bladder Cancer
Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
The purpose with this study is to evaluate treatment with radio chemotherapy (oxaliplatin and capecitabine) given concommitant with radiotherapy in patients with gastrointestinal tumors.
- Conditions
- Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer
- Trial name
- CORGI (NCT01016639)
- Testing
- oxaliplatin, capecitabine, radiotherapy
- Where
- 5 sites in Sweden
- Volunteers
- 106 people
- Sponsor
- Lund University Hospital
Cancer of the Head and Neck
Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer
The combination of oxaliplatin and gemcitabine is highly active in a wide variety of tumors including pancreatic, germ cell, breast, biliary, mesothelioma (Mitchell et al, 2002), and lung.
- Trial name
- NCT00256295
- Testing
- Gemcitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sai-Hong Ignatius Ou
Nasopharyngeal Carcinoma
Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study
To explore the progression-free survival rate (progression-free survival, PFS), overall survival (OS), objective response rate(objective response rate, ORR) and safety of patients with Sintilimab + GP chemotherapy combined with…
- Trial name
- NCT05417139
- Testing
- Immunotherapy+induction chemotherapy+radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer.
- Trial name
- NCT00761241
- Testing
- Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Platinum-resistant Ovarian Cancer (PROC), Immunotherapy
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib…
- Trial name
- NCT06600841
- Testing
- Immunotherapy（Adebrelimab）
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Extensive Stage Small Cell Lung Cancer
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may make tumor cells more sensitive to chemotherapy drugs.
- Trial name
- NCT00017251
- Testing
- oblimersen sodium, carboplatin, etoposide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Combination Chemotherapy in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at different times or combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003088
- Testing
- cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Where
- 19 sites in United States, Canada
- Volunteers
- 2,005 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003742
- Testing
- cisplatin, irinotecan hydrochloride, paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Endometritis
FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis
This randomized, double-blind, single-dummy, multicenter clinical study, led by Principal Investigator Xue Fengxia at Tianjin Medical University General Hospital (sponsor and primary trial institution) and funded by Zhuzhou…
- Trial name
- FKQJCE (NCT07485842)
- Testing
- FuKe Qianjin Capsules
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University
Diabetes Mellitus
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus
- Trial name
- NCT00286494
- Testing
- Alogliptin and pioglitazone, Pioglitazone
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 493 people
- Sponsor
- Takeda
Melanoma
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
The objectives of this study are to determine the safety and activity profile of multiple doses of MDX-010, and to determine the whether the addition of cytotoxic chemotherapy (decarbazine [DTIC]) can augment the effects of…
- Trial name
- NCT00050102
- Testing
- MDX-010 (CTLA-4)
- Where
- 9 sites in United States
- Sponsor
- Bristol-Myers Squibb
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- LUCERNA (NCT06901531)
- Testing
- zolbetuximab, Pembrolizumab, Capecitabine
- Where
- 252 sites in United States, Australia and 20 more
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Ganglioneuroblastoma, High Risk Neuroblastoma
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This phase II pilot trial studies the side effects and how well dinutuximab and sargramostim work when combined with chemotherapy in patients with high-risk neuroblastoma.
- Trial name
- NCT03786783
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
This study was designed to explore the safety and efficacy of Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy or Fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT05170594
- Testing
- Bevacizumab, chemotherapy, Fluzoparib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Esophageal Squamous Cell Carcinoma
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
Advanced esophageal squamous cell carcinoma patients who have failed first-line PD-1 inhibitor combined with chemotherapy lack a standard treatment option.
- Trial name
- NCT05990231
- Testing
- Cadonilimab combined Anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Mantle Cell Lymphoma
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ibrutinib and rituximab given together with venetoclax and combination chemotherapy work in treating patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT03710772
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer Metastatic, First-line Treatment
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
This prospective, multi-center, open-label, phase II, randomized controlled trial (CCICC-002b) is to evaluate the efficacy and safety of autologous cytokine-induced killer cell immunotherapy in combination with PD-1 inhibitor and…
- Trial name
- CCICC-002b (NCT04836728)
- Testing
- CIK cells injection, Sintilimab Injection, Pemetrexed
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital